Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$21.95
-3.4%
$22.38
$19.10
$29.55
$1.05B1.79471,045 shs266,696 shs
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
$14.09
-0.4%
$15.01
$8.26
$19.41
$1.20B-0.011.51 million shs1.45 million shs
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
$16.03
-6.4%
$16.34
$13.50
$25.00
$1.08B1.56177,629 shs116,089 shs
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$34.78
-3.2%
$30.95
$5.17
$39.50
$297.58M1.2452,891 shs49,131 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
+1.75%-2.32%-4.98%+3.74%+17.66%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
+4.97%+15.56%-5.54%+5.05%+13.20%
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
+5.74%+15.71%-1.27%+6.73%+15.21%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-0.25%+13.52%+16.50%+20.09%+3,592,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.9128 of 5 stars
3.53.00.00.01.82.50.6
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
3.2628 of 5 stars
4.50.00.00.01.44.20.6
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
3.8984 of 5 stars
3.50.00.04.21.84.20.0
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.00
Buy$31.1741.99% Upside
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
3.00
Buy$26.8990.84% Upside
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
3.00
Buy$22.0037.24% Upside
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SNWV, BLFS, LQDA, and PLSE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$22.00
6/12/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$23.00 ➝ $25.00
6/11/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$25.00 ➝ $23.00
6/2/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$36.00 ➝ $37.00
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$20.00 ➝ $23.00
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$29.00 ➝ $35.00
5/27/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/21/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/19/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetMarket Perform ➝ Underperform$13.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$87.76M11.96$0.12 per share182.27$7.52 per share2.92
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
$14M86.04N/AN/A$0.91 per share15.48
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
$700K1,540.48N/AN/A$1.87 per share8.57
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$36.19M8.22N/AN/A($1.49) per share-23.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$20.18M-$0.29N/AN/AN/A-11.81%-0.66%-0.58%8/14/2025 (Estimated)
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$130.39M-$1.58N/AN/AN/A-903.80%-177.91%-60.15%8/6/2025 (Estimated)
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
-$53.58MN/A0.00N/AN/A-68.44%-58.17%8/14/2025 (Estimated)
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-$31.37M-$4.56N/AN/A-89.86%N/A-145.76%N/A

Latest SNWV, BLFS, LQDA, and PLSE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$0.43N/AN/AN/A$3.90 millionN/A
5/9/2025Q1 2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/A-$0.66N/A-$0.66N/A$9.34 million
5/8/2025Q1 2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.03$0.04+$0.07-$0.01$22.22 million$23.94 million
5/8/2025Q1 2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million
5/8/2025Q1 2025
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
N/A-$0.25N/A-$0.25N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
N/AN/AN/AN/AN/A
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/A
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.01
4.73
3.74
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
2.08
2.93
2.91
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
N/A
15.58
15.58
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/A
0.40
0.28

Institutional Ownership

CompanyInstitutional Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
64.54%
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
76.95%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
42.53%

Insider Ownership

CompanyInsider Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.20%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
26.50%
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
71.50%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
36.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
44047.84 million46.46 millionOptionable
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
5085.49 million62.83 millionOptionable
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
14067.27 million19.17 millionOptionable
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
408.56 million5.43 millionN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioLife Solutions stock logo

BioLife Solutions NASDAQ:BLFS

$21.95 -0.77 (-3.39%)
Closing price 04:00 PM Eastern
Extended Trading
$21.92 -0.02 (-0.11%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Liquidia Technologies stock logo

Liquidia Technologies NASDAQ:LQDA

$14.09 -0.06 (-0.42%)
Closing price 04:00 PM Eastern
Extended Trading
$14.08 -0.01 (-0.07%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Pulse Biosciences stock logo

Pulse Biosciences NASDAQ:PLSE

$16.03 -1.09 (-6.37%)
Closing price 04:00 PM Eastern
Extended Trading
$16.45 +0.42 (+2.65%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Sanuwave Health stock logo

Sanuwave Health NASDAQ:SNWV

$34.78 -1.15 (-3.20%)
As of 04:00 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.